WO2003076465A3 - Downregulation of ca 125 tumor antigen and uses thereof - Google Patents

Downregulation of ca 125 tumor antigen and uses thereof Download PDF

Info

Publication number
WO2003076465A3
WO2003076465A3 PCT/CA2003/000341 CA0300341W WO03076465A3 WO 2003076465 A3 WO2003076465 A3 WO 2003076465A3 CA 0300341 W CA0300341 W CA 0300341W WO 03076465 A3 WO03076465 A3 WO 03076465A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor antigen
downregulation
methods
mammalian cell
negatively
Prior art date
Application number
PCT/CA2003/000341
Other languages
French (fr)
Other versions
WO2003076465A2 (en
Inventor
Claudine Rancourt
Alain Piche
Julie Beaudin
Original Assignee
Univ Sherbrooke
Claudine Rancourt
Alain Piche
Julie Beaudin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sherbrooke, Claudine Rancourt, Alain Piche, Julie Beaudin filed Critical Univ Sherbrooke
Priority to AU2003212142A priority Critical patent/AU2003212142A1/en
Priority to CA002518695A priority patent/CA2518695A1/en
Priority to US10/507,728 priority patent/US20060134116A1/en
Publication of WO2003076465A2 publication Critical patent/WO2003076465A2/en
Publication of WO2003076465A3 publication Critical patent/WO2003076465A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

The present invention is directed to negative modulators of CA 125 tumor antigen, a recombinant nucleic acids, vectors, host cells, pharmaceutical compositions, uses of the foregeoing for negatively modulating CA 125 tumor antigen in mammalian cell, preventing and treating a CA 125 tumor antigen associated disease in a mammal, as well as methods of prevention and treatment of such diseases and methods of negatively regulating CA 125 tumor antigen in a mammalian cell.
PCT/CA2003/000341 2002-03-11 2003-03-11 Downregulation of ca 125 tumor antigen and uses thereof WO2003076465A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003212142A AU2003212142A1 (en) 2002-03-11 2003-03-11 Downregulation of ca 125 tumor antigen and uses thereof
CA002518695A CA2518695A1 (en) 2002-03-11 2003-03-11 Downregulation of ca 125 tumor antigen and uses thereof
US10/507,728 US20060134116A1 (en) 2002-03-11 2003-03-11 Ca 125 tumor antigen function and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36330602P 2002-03-11 2002-03-11
US60/363,306 2002-03-11
CA002420494A CA2420494A1 (en) 2003-02-28 2003-02-28 Ca 125 tumor antigen function and therapeutic uses thereof
CA2,420,494 2003-02-28

Publications (2)

Publication Number Publication Date
WO2003076465A2 WO2003076465A2 (en) 2003-09-18
WO2003076465A3 true WO2003076465A3 (en) 2003-11-13

Family

ID=32873383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000341 WO2003076465A2 (en) 2002-03-11 2003-03-11 Downregulation of ca 125 tumor antigen and uses thereof

Country Status (3)

Country Link
AU (1) AU2003212142A1 (en)
CA (1) CA2420494A1 (en)
WO (1) WO2003076465A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013594A1 (en) * 1994-10-28 1996-05-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor-specific antibody fragments, fusion proteins, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013594A1 (en) * 1994-10-28 1996-05-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor-specific antibody fragments, fusion proteins, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAISMA H J ET AL: "Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 40, no. 6, 15 December 1987 (1987-12-15), pages 758 - 762, XP002963264, ISSN: 0020-7136 *
SCHULTES B ET AL: "Induction of CA125-specific B and T cell responses in MAb-B43.13 injected patients depends on complex formation of the MAb with circulating antigen in vivo", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1003, XP002202309, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
AU2003212142A8 (en) 2003-09-22
CA2420494A1 (en) 2004-08-28
WO2003076465A2 (en) 2003-09-18
AU2003212142A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
MX2022010175A (en) Flt3 binding proteins and methods of use.
EP1281717A3 (en) Putative ion channel
ATE374251T1 (en) COMPOSITIONS FOR GENE THERAPY OF DIABETES
WO2021092464A3 (en) Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
BR9809284A (en) Construct and process for high-level polynucleotide expression
WO2003076465A3 (en) Downregulation of ca 125 tumor antigen and uses thereof
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
WO2003037920A3 (en) Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2000006735A8 (en) Interferon alpha hybrids
CA2296070A1 (en) Novel mapk kinase
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor
WO2003102135A3 (en) Control sequences of the human corin gene
WO2000058464A3 (en) Rab genes and their uses
WO2004048531A3 (en) Modulation of death-associated protein kinase 1 expression
WO2003052377A9 (en) 41 human secreted proteins
CA2255748A1 (en) Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
WO2003068925A3 (en) Production of a protein delivery system for in vivo therapeutic treatment
WO2001088084A3 (en) A novel polypeptide, a superoxide dismutase 11 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref document number: 2006134116

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10507728

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2518695

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 10507728

Country of ref document: US

WWW Wipo information: withdrawn in national office

Country of ref document: JP